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The concept of using animal parts to save human life is 
bathed in ancient mythology. The Hindu religion notes 
that the elephant-headed god of wisdom, Lord Ganesha, 
was created by transplanting the head of an elephant on 
the traumatically beheaded child of Lord Shiva and his 
wife Parvati. Lord Ganesha is primarily worshipped as the 
god who removes obstacles and leads to success. Yet the 
field of xenotransplantation has not been rewarded by 
long-term clinical success, primarily related to the lack of 
understanding of the pathophysiology of xenotransplant 
rejection and, therefore, methods to control rejection. 
The principal driving force in the development of the 
field of xenotransplantation has been the lack of suitable 
donors for human transplantation. Isolated case reports of 
using animal kidneys appeared in the early 1900s from 
sources including pig, goat, nonhuman primate, and 
lamb.· With the discovery of the immune nature of organ 
rejection by Medawar2 and SnelP in the 1940s, much of 
the emphasis in organ transplantation focused on means 
to suppress the immune response. The development of 6-
mercaptopurine by Schwartz and Dameshak" provided 
the impetus for transplantation offoreign tissue. The ap-
plication of azathioprine to allograft transplantation re-
sulted in realization of the success of allotransplantation, S 
although limited by significant rejection episodes with 
graft and patient loss. It was not until the development of 
more effective immunosuppression (such as with cyclo-
sporine) that the magnitude of the limitation of azathio-
prine was apparent. Nevertheless, in the 1960s, a number 
of subhuman primate-to-human kidney transplants were 
attempted. Even with this relatively ineffective form of 
immunosuppression, function of subhuman primate 
(chimpanzee) xenografts could be demonstrated (in one 
patient up to 9 months after transplantation).6 In 1963, 
seven patients received baboon kidneys, all of which func-
tioned immediately'?' 8 These heterografts maintained di-
alysis-free function for up to 60 days. However, in spite of 
the high doses of azathioprine and prednisone, the grafts 
were eventually rejected. 
In 1968, the guidelines for defining brain death were 
published in the Journal o/the American Medical Associa-
tion.9 Almost overnight, the availability of brain dead, 
heart-beating cadaver donors eliminated the need to con-
tinue the quest for nonhuman donor organs. Widespread 
access to dialysis and the government financing of the 
end-stage kidney disease program allowed patients with 
kidney failure to live and wait for kidney transplantation, 
whereas previously kidney transplantation was the only 
alternative to death. Interest in xenotransplantation of 
kidneys gave way to pretransplant management with dial-
ysis and more timely transplantation with optimally func-
tioning human kidney allografts. 
Refinements of surgical techniques, improvement in 
immunosuppression, development of effective organ 
preservation, and broadening indications for transplanta-
tion have pushed the success of transplantation into the 
realm of acceptability, with transplantation being the 
treatment of choice for many patients with end-stage 
organ disease. Yet the success of allograft transplantation 
has again highlighted the consequences of organ shortages, 
as witnessed by the increasing number of deaths occurring 
while waiting for transplantation. This is particularlv 
highlighted in certain candidate populations, such as chil-
dren, in whom donor scarcity is even more apparent. Such 
was the rationale for the only attempt at xenotransplanta-
tion in the cyclosporine era. The shortage of neonatal 
hearts for treatment of severe congenital cardiac anoma-
lies prompted Dr. Leonard Bailey to use a baboon heart 
for transplantation into an infant ("Baby Fae") with a hy-
poplastic left ventricle in 1983. 10 Although that immuno-
suppressive regimen included cyclosporine, the heart was 
eventually rejected by antibody-mediated mechanisms 20 
days after transplantation. No further attempts at xeno-
transplantation were done for almost a decade, until three 
attempts at liver xenotransplantation were reported in 
1992 and 1993. 
PATHOLOGY 
The pathology of the rejection process was not well under-
stood during the early era of xenotransplantation, al-
though the descriptions of the rejected xenograft kidneys 
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from both baboons and chimpanzees are consistent with 
the pathophysiology of xenograft rejection as we under-
stand it today. Lymphocytotoxic antibodies were first rec-
ognized in 196511 as a cause for antibody-mediated rejec-
tion. In the baboon-to-human kidney xenotransplant 
cases just described, heterospecific antibodies could be de-
tected bound to the kidney xenografts.7. 12 Dr. Kendrick 
Porter concluded, 
In the resulting (heterograft) rejection process, cellular 
infiltration and peritubular capillary destruction are 
prominent early pathologic features, but by nine days the 
vasculonecrotic element is marked. There is circumstan-
tial evidence to suggest that, whereas the peritubular cap-
illary damage is mediated by cell-bound antibody, the fi-
brinoid necrotic vascular lesions are caused by 
circulating antibody. 
Porter noted that the rejected xenografts showed variabil-
ity in the histology, from total infarction to cellular infil-
trates to interstitial edema and tubular necrosis to only in-
timal hypertrophy. The antibody component of rejection 
has been the central issue of xenotransplantation since 
that time. 
CaIne developed the terms discordant and concordant 
xenotransplantation to distinguish between different types 
of rejection that occurred after cross-species transplanta-
tion. 13 Calne suggested that cellular rejection would be the 
the primary cause of graft loss in concordant xenotrans-
plants, whereas antibody-mediated rejection would be 
more apparent in discordant combinations. The titer of 
preformed xenoantibodies and ease of inducing xenoanti-
bodies were proposed to be able to provide an assessment 
of phylogenic diversity; hence, the designation of discor-
dant and concordant combinations. Somewhat mislead-
ingly, the patterns of discordant and concordant rejection 
have been used synonymously with disparate and closely 
related cross-species transplantation, respectively. Unfor-
tunately, the definition is blurred by the variable suscepti-
bility of different organs to antibody-mediated rejection. 
For instance. liver xenografts appear to be less susceptible 
to xenoantibody rejection compared with heart and kid-
ney xenografts. 14 These findings have also been found in 
allografts that have been placed into a hostile, preformed 
antibody environment. I' 
In xenotransplantation, preformed antibodies occur 
naturally without the necessity of prior exposure to anti-
gens from other species of animals. These antibodies are 
capable of mediating rejection, which may be hyperacute 
or may take place over a period of days to weeks. It is 
thought that these naturally occurring antibodies are the 
results of exposure to common environmental antigens, 
such as those composed by isoagglutinins of the ABO sys-
tem. These antibodies react with various glycolipids and 
glycoproteins on the cell surface of the xenograft. The an-
tigenic determinants that are targets of xenoantibody 
binding have been the focus of a great deal of research. It 
has been suggested that the primary cell surface epitopes 
for binding to xenoantibodies are carbohydrate in nature. 
One such candidate is the alpha 1-3 linkage of the subter-
minal and terminal galactose residues, 16-18 although other 
candidates have been identified. 19 
Generally, xenoantibodies are of the immunoglobulin 
M (lgM) class, but high titers of immunoglobulin G (lgG) 
can be induced by sensitization. In some discordant xeno-
transplant combinations, IgM and IgG can be shown to 
pre-exist in high titers, such as in t~e guinea pig - t~ra~I the 
pig-to - rhesus monkey, and the plg-to-dog combmatIons. 
In concordant xenotransplant combinations, usually only 
low-titer IgM exists, such as in the hamster-to-rat, the fox-
to-dog, and the rhesus monkey - to-baboon combinati~nsK 
However, in both discordant and concordant combma-
tions, sensitization after xenotransplantation generally re-
sults in an abrupt rise in the IgM titer followed shortly by 
an increase in the IgG titer. 
The nature of the B-Iymphocytes, which synthesize 
xenoantibodies, has been the subject ofinvestigation, with 
hopes that identification of these cells may lead to specific 
therapies to eliminate them. It has been suggested that 
CD5+ B cells are the most likely candidates as the source 
ofxenoantibody production.20 In the rat, these cells can be 
identified in the spleen and are located in the splenic red 
pulp and in the marginal zone. Thus, the rationale for a 
role of splenectomy in xenotransplantation is to reduce 
the B cell load, which is thought to synthesize xeno-
antibodies.21• 22 
Independent of the nature of immunoglobulin class of 
preformed antibody involved in triggering antibody-
mediated rejection, the pathophysiology of the acute in-
flammatory response is similar. Preformed antibodies 
trigger inflammation and injury by their deposition on the 
endothelium of the vascularized graft. These antibodies, 
in tum, activate complement, which, in tum, activates a 
characteristic cascade ofinflammatory, nonspecific medi-
ators, such as recruitment of polymorphonuclear leuko-
cytes, platelet adhesion, and degranulation followed by in-
travascular thrombosis. Complement activation can 
occur via the classic and alternative complement path-
ways (Fig 54-1). In the classic pathway, the Clq compo-
nent ofC I is activated after binding to the Fc region ofIgM 
and IgG. This, in tum, results in Clr and Cis activation 
and the generation of the C Iqrs protease complex, in tum 
leading to C4 and C2 cleavage, producing the C3 conver-
tase, C4b2a complex. C3 is then cleaved to produce the 
biologically active components C3a and C3b. In the alter-
native pathway, complement can be activated via immu-
noglobulins A and E and other nonimmunological fac-
tors, such as various polysaccharides and bacterial 
antigens. Activation ofC3 occurs via nonspecific cleavage 
to generate C3b. The common, final pathway of comple-
ment activation is via C5 cleavage, which generates C5b, 
which, in turn,leads to the assembly of the C5b-C9 mem-
brane attack complex (MAC). This MAC binds to the cell 
surface, resulting in a porous membrane that is susceptible 
to osmotic pressure, leading to either cell damage or cell 
death. 
The importance of complement in the pathophysiology 
of antibody-mediated rejection is shown in studies in 
which complement is depleted. Cobra venom depletes the 
C3 and C5 components, resulting in paralysis of the com-
plement system. Adachi and coworkers were able to ob-
tain prolongation of discordant xenograft survival with 
the addition of cobra venom factor along with cyclospor-
ine and an anti platelet agent.23 Other evidence of the im-
portance of C5 in the process of xenograft hyperacute re-
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Figure 54-1 Classic and alternative pathways 
of complement activation leading to formation of 
the membrane attack complex (MAC). 
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jection is the ability of a sesquiterpene compound with 
anticomplement activity to prolong xenograft survival. 
K 76 is thought to block the C5 step of complement activa-
tion and also accelerates the degradation ofC5b.24 Admin-
istration of 200 mg/kg to rats undergoing heterotopic 
guinea pig heart transplantation (discordant combina-
tion) resulted in marked prolongation of survival from 8 
minutes to more than 8 hours.25 
Cells express naturally occurring proteins (regulators of 
complement activation) on the cell surface, which help to 
modulate the effects of various complement-activated 
components. The molecules are thought to provide an in-
trinsic mechanism to limit the amplification of comple-
ment activation. Homologous restriction factor (CD59) 
and decay-accelerating factor (CD55) are two proteins 
that have been described as mediators of complement ac-
tivation. CD59 is thought to act by inhibition of the inser-
tion ofC9 into MAC, thus aborting the terminal attack se-
quence of complement activation.26 Decay-accelerating 
factors limit the generation of classic and alternative com-
plement pathway convertases.27 The importance of these 
modulators has been demonstrated by experiments that 
have enhanced expression of these proteins by gene trans-
fection.28 The activity of these complement modulators 
are thought to be species specific and help to explain the 
phenomenon of "homologous species restriction. "29 This 
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phenomenon is most easily seen when the addition ofho-
mologous complement to susceptible target cells does not 
effectively cause lysis, whereas the addition of heterolo-
gous complement leads to effective cell lysis. 
Cell damage also occurs by activation of other in-
flammatory pathways. Reactive oxygen metabolites, 
prostaglandins, and cytokines can be generated by the deg-
radation products of complement activation. Polymor-
phonuclear leukocytes and macrophages are attracted to 
the site of inflammation as a result of the presence of the 
C5a fragment, which results in the release of lysosomal 
enzymes and resultant cell damage. C3b enhances adhe-
sion of these cells to damaged cells and also enhances 
binding of platelets, which may lead to degranulation and 
release of vasoactive substances, such as serotonin and 
histamine, both increasing vascular permeability. 
Thrombosis of the microvasculature is enhanced by the 
loss of membrane-associated heparan sulfate from the en-
dothelial cell. 30 Heparan sulfate proteoglycan is present in 
the endothelial cell layer of normal vessels and helps to 
maintain a local anticoagulant environment by activation 
of antithrombin III, an inhibitor of thrombin generation. 
The release of tissue factors from injured cells promotes 
thrombosis. 
The role of the cellular immune response in the destruc-
tion of xenografts has been difficult to determine mainly 
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because of the overwhelming rapid destruction of these 
grafts by naturally occurring xenoantibodies. Neverthe-
less, there is sufficient evidence that xenogeneic cells can 
elicit a strong cell-mediated response. Using discordant 
combination of human T cells to xenogeneic porcine stim-
ulator cells, several investigators have shown that un-
primed human T cells are capable of responding to por-
cine stimulators by proliferation and cytotoxicity.31,32 
The characterization of the mechanisms of sensitization in 
vitro has not yet been clearly determined (ie, whether re-
cipient antigen presenting cells require xenoantigen pro-
cessing or whether xenoantigens can be presented directly 
by xenogeneic cells). 
CURRENT XENOTRANSPLANTATION RESEARCH 
The prospect of using animal organs for transplantation 
has been limited by the ability to control immune reactiv-
ity. The area that requires further investigation is the man-
agement of the antibody component of the immune 
response, which has been refractory to standard cyclo-
sporine and steroid therapy. 
Although a number of animal models have been devel-
oped for both discordant and concordant xenotransplan-
tation, long-term successes have been limited for the most 
part to concordant combinations. The lack of high-titer 
preformed xenoantibodies has avoided the almost imme-
diate destruction of discordant xenografts, which has been 
difficult to prevent or treat. Nevertheless, even in the dis-
cordant combinations, significant prolongation of xeno-
graft survival has been reported when antibody deple-
tion33 or depletion of complement is used (see prior 
discussion). 
Techniques to prevent or mitigate humoral allograft or 
xenograft rejection have been summarized elsewhere. 34 Of 
these approaches, prostaglandin therapy appears to have 
some potential with minimal side effects. Prostaglandin 
can mitigate the xenograft rejection in a number of experi-
mental xenograft models. 35-37 There were early reports 
that prostaglandin would be effective against B cells.38 The 
poorer prognosis of lymphocytotoxic crossmatch-
positive liver allograft recipients was eliminated when 
prostaglandin was added to tacrolimus (FK506).39 Al-
though prostaglandin is weakly immunosuppressive,40, 41 
its unique effect in the xenograft system is via different 
targets than those of classic immunosuppression. Prosta-
glandins diffusely modify effectors of the inflammatory 
response. including cytokines.42 
Although the duality of humoral and cellular mecha-
nisms of xenograft rejection is generally accepted. it is also 
common knowledge that the antibody component is diffi-
cult to modulate. Consequently, additional strategies have 
been developed to minimize antibody-mediated rejection. 
Using a hamster-to-rat cardiac heterograft model. modest 
titers (1: 16- 1 :32) of preformed heterospecific cytotoxic 
antibodies destroy the heart xenograft within 3 days in un-
treated rat recipients before there is histopathological evi-
dence of lymphocyte infiltration. By itself, tacrolimus, 
which prevents T-cell activation and cytokine secretion, 
was able (at doses of2 mg/kg/day) to prolong survival by 
only 1 day. Monotherapy with a number of ant iprol if era-
tive drugs,43-49 including those that suppress purine 
(RS61443) or pyrimidine (brequinar) synthesis, as well as 
the conventional anticancer drug cyclophosphamide 
could increase survival but did not permit consistent 
chronic survival. However, when some of these antiprolif-
erative drugs were added to tacrolimus for the first 2 post-
operative weeks, further survival under continued tacro-
limus alone became routinely possible.5O 
After hamster-to-rat orthotopic liver xenotransplanta-
tion, the perioperative survival of the liver, with its well-
known resistance to antibodies, was less dependent than 
the heart on the antimetabolite component of the com-
bined drug therapy, but the results also were significantly 
improved with the antimetabolite drugs, including cyclo-
phosphamide. Thus, it is clearly possible, with tacrolimus-
based immunosuppression, to transplant heart and liver 
xenografts with consistent long-term survival of healthy 
recipients. These results are remarkable in the context of 
the information on this difficult model published in the 
literature. 51-55 Van Den Bogaerde et al5S emphasized the 
separateness of the humoral and cellular mechanisms of 
xenograft rejection. 
The therapeutic benefit of the adjuvant agents corre-
lated with their ability to inhibit the antihamster antibody 
response postoperatively. Once the first 2 weeks had 
passed, treatment with antiproliferative agents was no 
longer necessary. Other circumstantial evidence supports 
the conclusion that the effectiveness of the adjuvant drugs 
is primarily by reducing the humoral antibody response. 
flow cytometric studies of splenic B-cells after stimulation 
with xenograft tissue revealed that the addition of cyclo-
phosphamide totally abrogated the blastic response of the 
CD5+ B cell, which is thought to synthesize heterograft-
specific antibody.21 
Because the spleen produces antidonor antibodies to 
xenotransplants, the effect of splenectomy combined with 
tacrolimus on heart and liver xenograft survival has also 
been studied. Using the hamster-to-rat model, cytotoxic 
antibody titers were markedly suppressed during the 
whole period of observation in both liver and heart xeno-
transplanted animals that received both tacrolimus and 
splenectomy. In contrast, untreated liver xenografts had 
cytotoxic antibody titers by day 7 ( 1 :8192), whereas heart 
xenografts had a cytotoxic antibody titer of I :256 on day 3. 
Thus, splenectomy may be an adjuvant in the strategy to 
control humoral rejection in clinical xenotransplantation. 
Splenectomy as an adjuvant immunosuppressant mea-
sure was introduced in 196256 and used extensively in the 
early days of transplantation, 57 especially for treating pa-
tients with preformed antibody states.S8 
The need to inhibit complement after liver xenotrans-
plantation may be limited to a short period after implan-
tation. It is clear that the principal source of complement is 
the liver.59 With the ability to obtain long-term survival of 
liver xenografts in animal models, Valdivia et al have 
shown that the transition of complement from recipient to 
donor sources may have a long-term protective effect on 
the transplanted xenograft.6O The phenomenon of homo 1-
ogous species restriction of complement activation may 
subsequently protect the xenograft from further comple-
ment-mediated damage. 
SUMMARY OF THREE CUNICAL 
LIVER XENOGRAFT ATTEMPTS 
Within an 8-month period, three attempts were made to 
transplant liver xenografts in the United States. The liver 
appeared to be a logical starting point because of the 
known relative resistance of the liver to antibody-
mediated rejection IS compared with the heart and kidney 
and also because of the lack of artificial support, such as di-
alysis or ventricular assist devices. Two baboon-to-human 
liver transplants were performed at the University of Pitts-
burgh, and one pig-to-human liver transplant was per-
formed at Cedars-Sinai Medical Center in Los Angeles. 
Pig-to-Human Liver Xenotransplantation 
In the case of the pig-to-human liver transplant, the trans-
plant group at Cedars-Sinai, headed by Leonard Ma-
kowka, had prepared a protocol for the temporary support 
of a failing human liver ("bridge to transplant").6' The 
protocol was designed to treat patients with acute deterio-
ration of liver function, necessitating emergency support 
and transplantation. and was written in response to the 
death of a patient before the availability of a human liver 
for transplantation. The Institutional Review Board, 
along with the Ethics Committee, approved the protocol, 
which was designed to support a failing human liver until a 
permanent human liver replacement could be found. The 
single patient who underwent transplantation at that 
center was given a pig liver only after exhaustive efforts 
had been made to find a human liver and after the condi-
tion of the patient deteriorated. The patient's family gave 
consent after detailed discussions. 
Pigs can grow to weigh more than 300 pounds. The size 
difference can be minimized by selecting a donor organ 
that is slightly larger than that ofa human. Selection of the 
donor was based on size and was obtained from a breeding 
farm after a period of quarantine. The pig was sedated and 
given inhalation anesthesia during liver procurement. 
The recipient of a pig liver was a 26-year-old woman 
with accelerated liver failure from autoimmune hepatitis 
who progressed into grade 3-4 coma. Most humans have 
high titers of preformed antibodies against pig tissue. 
which is not related to ingestional exposure to pork.62 The 
patient was treated to remove preformed anti-pig antibod-
ies using a combination of plasmapheresis and specific an-
tibody removal by passage of her blood through a set of pig 
kidneys. The immunosuppression was based on cyclo-
sporine. cyclophosphamide, prostaglandin E" and azath-
ioprine. The liver was placed in a heterotopic position. 
The liver appeared to function for 20 hours, as demon-
strated by an initial decrease in the serum lactate level and 
the presence of bile. However, the ammonia level did not 
fa1\ and by 20 hours after transplantation several clinical 
parameters worsened, and the patient died from brain 
death 26 hours after transplantation. The liver appeared to 
have undergone extensive infarction from hyperacute re-
jection in spite of the lowering of the antibody titer using 
plasmapheresis and pig kidney perfusion.63 These find-
ings are consistent with those described by Chantrel et al 
using a pig-ta-primate model of liver and kidney immu-
noabsorption, in which rapid reaccumulation of xeno-
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reactive antibodies was observed after initial immuno-
absorption.64 
Baboon-ta-Human Liver Xenotransplantation 
The rationale for the baboon-to-human liver transplant 
was for treatment of end-stage liver disease caused by 
chronic active hepatitis B. Hepatitis B is the leading cause 
of liver disease in the world, affecting more than 250 mil-
lion people. It has been shown that human liver transplan-
tation into patients with hepatitis B (especially with posi-
tive viral replication markers, eg, hepatitis B e antigen or 
hepatitis B DNA positivity) is associated with a high rate of 
reinfection of the new liver and an accelerated cirrhosis 
after transplantation.6s, 66 In many parts ofthe world this 
disease is considered a contraindication to human liver 
transplantation. Experimental agents have been used with 
only limited success in the prevention of recurrent hepati-
tis B. Baboons have been thOUght to be resistant to the de-
velopment of chronic active hepatitis B (Landlord RE, 
Southwestern Primate Facility, San Antonio, TX, unpub-
lished data, 1993). Thus, the principal benefit to the pa-
tients enrolled in this trial was the possibility that the ba-
boon liver would not be reinfected and that the stigmata of 
chronic liver disease would be reversed. The transplant 
was, therefore, considered a permanent replacement for 
the failing human liver. 
Nonhuman primates offer a number of advantages in 
the study ofliver transplantation and as donors for xeno-
transplantation. Unlike the canine or porcine liver, the 
liver anatomy of nonhuman primates is similar to that of 
humans. Among the higher order primates, similarities 
exist between the major histocompatibility complex and 
the cellular markers found in the immune system. The 
blood groups are similar to the A and B blood types, al-
though 0 blood types are quite rare.67 
Primates are composed of two suborders: Prosimii and 
Anthropoidea. Prosimian primates resemble squirrels or 
rats more than true monkeys. The Anthropoidea suborder 
can be further subdivided into five different families: New 
World monkeys, Old World monkeys, lesser apes, great 
apes, and humans. From an investigational standpoint, 
the most frequently used species are the Old World mon-
keys. This family includes rhesus monkeys (Macaca mu-
latta), cynomologus monkeys (M. jascicularis), and ba-
boons (Papio cynocephalus). Great apes include the 
chimpanzee (Pan troglodytes) and gorillas (Gorilla gorilla) 
but are not used in large numbers as donors because of 
their endangered classification, although they approxi-
mate humans in genetic similarity and size more than do 
lesser apes. 
The liver anatomy in primates is similar. with a right 
and left lateral lobe placed dorsally and a single large ven-
tral central lobe. The liver of the Macaca and Papio is no-
table for lobation, with four identifiable lobes. In the 
higher order primates, the central lobe fuses with the right 
and left lateral lobes. The quadrate lobe is much more 
narrow in nonhuman primates than in humans, and the 
caudate lobe may encircle the circumference of the infe-
rior vena cava. The ligamentous attachments are similar 
to those described in humans. The blood supply to the 
- --------- -----
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liver is similar in the Anthropoidea, with a great variation 
in the arterial blood supply. The portal venous system is 
essentially identical in the higher order primates. The he-
patic venous drainage is similar to that of humans, with 
small, short hepatic venous tributaries draining the right 
and central lobes and with two large hepatic venous 
branches (one right and one left). 
In all primates, the gallbladder lies closely attached to 
the right or central lobe. The arterial supply is usually from 
a branch from the right hepatic artery. The cystic duct 
joins the common hepatic duct a variable distance to form 
the common bile duct before emptying into the duo-
denum. 
Baboons are physically smaller than humans. The max-
imum weight of an adult male baboon is about 65 to 70 
pounds. Unlike the heart, a small liver can rapidly grow to 
accommodate the function expected by the size of the re-
cipient,68 although the largest baboons were selected for 
the clinical trials in liver xenotransplantation. A closed 
colony of bred baboons was screened to match blood 
groups with the recipients, and aU known infectious agents 
were screened. including serologies for retroviruses (sim-
ian immunodeficiency virus [SIV], simian retrovirus 
[SR V], simian T lymphotrophic virus [STL V], human 
immunodeficiency virus [HIV] types I and 2, foamy 
virus, and human T cell lymphotropic virus), DNA vi-
ruses, cytomegalovirus (CMV), Epstein-Barr virus, herpes 
virus (SA8 and varicella-zoster virus), hepatitis viruses 
(hepatitis A, hepatitis B, and hepatitis C viruses), and other 
potentially transmittable agents (such as Marburg virus, 
encephalomyocarditis virus, lymphocytic choriomenin-
gitis virus, hemorrhagic fever virus, tuberculosis. and tox-
oplasma).69 The animals were thoroughly examined and a 
complete biochemical analysis and compatibility by histo-
compatibility testing of the donors made. A number of 
suitable donors were screened to select the donor with the 
lowest reactivity by lymphocytotoxicity studies, using the 
recipients' serum. Once selected, the animals were quar-
antined. No other preparation was required, and the ani-
mals were sedated and given inhalation anesthesia during 
procurement. A certified veterinarian was present to en-
sure compliance to animal handling standards. A com-
plete autopsy was performed after the Ii ver had been taken 
out for transplantation. The protocol for this trial was de-
signed with the input of a panel of extramural transplant 
specialists, the Institutional Review Board, a panel of in-
fectious disease consultants, and intramural specialists in 
histocompatibility, hepatology, immunology, and trans-
plantation. After a detailed discussion of informed con-
sent. both patients and their families consented to the 
procedure. 
The following summarizes the clinical courses of the 
two baboon-to-human liver transplant patients.7o The first 
patient was a 35-year-old ma,n who received a number of 
blood transfusions as a result of previous trauma. In 1989 
he also underwent splenectomy after a motor vehicle acci-
dent. That year. the patient was also found to be HIV posi-
tive. but his CD4 lymphocyte count was normal as were 
the in vitro mitogen responses. His blood group was type 
A. The second patient was a 62-year-old man in whom the 
cause of hepatitis B was not determined. His blood group 
was type B. He had not had any previous abdominal oper-
ations. In both patients, the principal complications of 
chronic hepatitis B were poorly controUed edema, fatigue, 
ascites, encephalopathy, and gastrointestinal bleeding. 
Because of the nature of their liver disease, these patients 
were not considered candidates for human liver transplan-
tation, but because of the severity of complications, xeno-
transplantation was considered an experimental option. 
In both patients receiving a baboon liver, slight techni-
cal modifications were made to the standard orthotopic 
liver transplant technique, using the piggyback technique 
described for smaller donor liver venous outflow recon-
struction.71 In the first patient, a 600-g liver was removed 
from the baboon and implanted; the second patient re-
ceived a donor liver weighing 450 g. Because of the consid-
erable size discrepancy, the portal vein of the first donor 
was anastomosed to the recipient's left portal vein branch. 
In the second patient, an end-to-end portal vein anasto-
mosis was done. In the first patient, the donor's celiac axis 
was anastomosed end to end onto the recipient's common 
hepatic artery. In the second patient, the arterial recon-
struction required a donor carotid artery interposition 
graft to the recipient's supraceliac aorta. In both patients, a 
Roux-en-Y choledochojejunostomy was used to recon-
struct the biliary drainage system. 
The cold ischemia time was 80 minutes in the first pa-
tient and 231 minutes in the second patient. Both pa.tients 
experienced uneventful intraoperative courses after reper-
fusion of the baboon liver, and the clinical impression was 
one of immediate function of both xenografts. Immuno-
suppression used a combination of tacrolimus, steroids, 
prostaglandin E., and cyclophosphamide. Of the various 
anti metabolites that were shown to provide a synergistic 
immunosuppressive effect in experimental xenotrans-
plant models, cyclophosphamide was chosen because of 
its relative availability and its proven usefulness in allo-
transplantation. 72 Except for slightly higher doses of ta-
crolimus in the first 2 posttransplant weeks. the doses of 
tacrolimus. steroids. and prostaglandin were within stan-
dard therapeutic dosages. Cyclophosphamide administra-
tion was started 2 days before transplantation and contin-
ued for a total of 56 days and 10 days (patient I and patient 
2. respectively) at dosages ranging from 0.07 to 10.6 
mg/kg/day. 
The first patient awoke promptly after transplantation 
and was extubated after 17 hours. He was placed on an oral 
diet on posttransplant day 5. The liver function tests re-
turned toward normal by the second posttransplant week. 
and the levels oftransaminases returned to normal within 
the first week (Fig 54 - 2). The second patient never re-
gained a level of consciousness that permitted weaning 
from the ventilator. In addition. the quality of the liver 
function in the second patient was suboptimal, with per-
sistent hyperbilirubinemia during the entire postoperative 
course (Fig 54 - 3). Nevertheless. in both patients, there 
was evidence of adequately functioning liver mass. such as 
normalization of the coagulation with normal prothrom-
bin time, correction of the hyperammonemia, normal ar-
terial ketone body ratio (a manifestation of hepatic energy 
stores), and clearance of serum lactate. 
A number of liver biopsies were obtained throughout 
the posttransplant course.73 The pathological changes in 
both patients revealed an early element of mild antibody 
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Figure 54 - 2 Clinical course of first 
baboon-to-human liver transplant patient. 
(From Starzl TE. Fung J. Tzakis A. et al. 
Baboon-to-human liver transplantation. 
Lancet 341(8837):65-71. © by The Lancet 
Ltd. 1993,) 
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attack without substantial cell-mediated rejection. The 
earliest post perfusion biopsies (4 hours after perfusion) re-
vealed some mild antibody-mediated insult. Immunoflu-
orescence revealed binding of immunoglobulin with com-
plement deposition; however, neither endothelial injury 
nor platelet aggregation was seen. Polymorphonuclear cell 
infiltration and natural killer cells were seen in these early 
biopsies. In the first patient, a biopsy taken on day 12 re-
vealed Kupffer cell hypertrophy, mild centrilobular hepa-
tocyte swelling, and cholestasis with a mild mononuclear 
portal and perivenular infiltrate. This infiltrate was pre-
dominantly T cell and was consistent with a mild cellular 
rejection with minimal antibody injury. Later biopsies 
were remarkably free from rejection, either antibody or 
cellular. Mild cholestasis was" noted in some of these later 
biopsies. In the first patient, the final antemortem biopsy 
was taken on posttransplant day 64 and revealed obvious 
bile infarcts with mural necrosis of segments of the septal 
bile ducts. In the second patient. an intraoperative biopsy 
taken on posttransplant day 4 revealed indirect evidence 
10 20 30 40 50 60 70 
Days 
of antibody-mediated rejection, and a subsequent splen-
ectomy was performed. 
Complications in both patients occurred, some possibly 
related to technical issues and others resulting from the 
immunosuppression used to prevent rejection. There 
were a number of infectious complications related to both 
technical causes and immunosuppression. Many of these 
infectious agents are typical of the microorganisms seen in 
allotransplantation (eg, Staphylococcus. Candida. CMV, 
Enterococcus. and Aspergillus). In the first patient, the 
contribution of the positivity of both the recipient and 
donor to CMV to the subsequent CMV infection is not 
known. Attempts to determine the origin of the CMV. ei-
ther human or baboon. failed because of the inability to 
culture the CMV from clinical samples in sufficient quan-
tity to subtype. The susceptibility of both baboon and 
human CMV to ganciclovir diminishes the impact of the 
origin of this virus. 
Other complications included renal failure and dialysis 
dependence as well as a number of iatrogenic com plica-
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tions. The cause of the renal failure was probably multi-
factorial, with contributions from drug toxicity (including 
tacrolimus, amphotericin, vanocomycin. ganciclovir, and 
trimethoprim-sulfa-methoxazole), and rejection. The first 
patient was able to be taken off hemodialysis for a short pe-
riod but required resumption for uremic gastritis. The sec-
ond patient did not recover any significant renal function 
during the 26 days after xenotransplantation. 
The causes of death in both patients were also multifac-
torial. In the first patient, a rise in both the alkaline phos-
phatase and total bilirubin levels prompted a percutane-
ous transhepatic cholangiogram on posttransplant day 61. 
Within an hour after the procedure, the patient became 
hypotensive, febrile, and coagulopathic. This patient was 
intubated and was stabilized and improved over the last 5 
days of his life. A positive culture for Aspergillusjlavus was 
noted and full-dose amphotericin administration was 
24 26 
Figure 54-3 Clinical course of second 
baboon-ta-human liver transplant patient. (From 
Starzl TE. Tzakis A. Fung JJ. et al. Human liver 
xenotransplantation. Xeno 1 :4-7. 1993.) 
started. On the last day of his life, the patient was being 
weaned from the ventilator, with stable coagulation fac-
tors, and was hemodynamically stable. The patient sud-
denly deteriorated neurologically, and a computed tomo-
graphic scan of the head revealed a massive subarachnoid 
bleed. At autopsy, the cause of death was determined to be 
subarachnoid hemorrhage resulting from angioinvasive 
aspergillosis. In this patient, two foci of aspergillosis were 
found in the lung, with focal dissemination to the kidney 
and brain. The bile ducts of the liver were slightly dilated, 
and numerous bile infarcts were detected. The biliarY 
anastomosis appeared somewhat stenotic. Although the 
patient was in kidney failure, the kidneys appeared intact. 
and there was no evidence ofimmune complex deposition 
in the kidney. 
The second patient died on posttransplant day 27 from 
complications of peritonitis. It is likely that the high doses 
of corticosteroids, used to control early immunological 
damage, were responsible for poor tissue healing, leading 
to a leak from the enteric anastomosis. 
Both baboon livers were shown to grow rapidly from 
baseline values of600 gand 450 gto more than 1555 gand 
1741 g, respectively. Radiographically, there was evidence 
of accommodation of the vasculature to the growth in liver 
size. Finally, the baboon liver did affect the protein profile 
of both patients. Liver-specific proteins could be shown to 
be of baboon origin by serum protein electrophoresis. In 
both patients, the recipients acquired the same coagula-
tion profile as the baboon and retained a normal pro-
thrombin time and coagulation profile.74 No evidence of 
adverse effects of these proteins could be found, such as 
immune-mediated kidney injury. Total complement 
levels were depleted for 1 to 2 weeks after liver xenotrans-
plantation, similar to that reported in liver allotransplan-
tation across a positive lymphocytotoxic crossmatch.75 
Serial determinations of hepatitis B surface antigen 
failed to find serological recurrence of hepatitis B, and im-
munostaining for hepatitis B virus in the liver biopsies also 
confirmed lack of reinfection. Because the period of fol-
low-up was short, no definitive conclusions can be reached 
regarding the possibility oflong-term resistance of the ba-
boon liver to hepatitis B recurrence; however, the most 
sensitive assays using polymerase chain reaction could not 
detect hepatitis B DNA in the transplanted liver.76 
In summary, baboon livers transplanted into two 
humans, using four agent immunosuppression, were able 
to sustain life for 70 and 26 days, respectively. The livers 
appeared to function during this period, although liver 
function was compromised during the later posttransplant 
course. In these xenotransplant cases, it is conceivable that 
the unrecognized biliary stasis syndrome was a manifesta-
tion of an unrecognized technical limitation or, more 
likely, an atypical manifestation of rejection. The con-
trasting posttranspiant courses of the two patients may be 
partially explained by differences from an immunological 
standpoint (splenectomy and HIV infection in the first pa-
tient) and patient selection (the second patient was elderly 
and more critically ill at the time of transplantation). 
ETHICAL ISSUES 
A number of ethical concerns regarding the field of xeno-
transplantation have been raised. including issues of in-
formed consent. safety, and animal rights concerns. Many 
issues surrounding the field ofxenotransplantation are ex-
tensions of debates regarding broader issues of health care. 
biomedical research. organ transplantation. and human 
experimentation. We do not address the debate on animal 
rights because the arguments for using animals for bio-
medical research are far beyond the scope of this 
discussion. 
The principal concerns that have attracted the attention 
of the scientific community and the medical ethicists deal 
with informed consent. safety of the experiment. and 
timeliness or appropriateness of the procedure. The issue 
of timeliness or appropriateness of xenotransplantation is 
the least controversial. The need for finding a solution to 
the organ shortage is real. The number of human donors 
in the United States has not increased appreciably in the 
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past 5 years. For only 25% of the potential brain dead 
donors is consent given for donation. The effectiveness of 
seatbelt laws and drunk-<lriving laws has diminished the 
"normal" pool of head trauma patients. The drop in this 
category of donors has been compensated for by expand-
ing the criteria acceptable for donors, including expanded 
age criteria and the inclusion of medical conditions in the 
donor that were once excluded. Unless there is a major re-
form in public attitudes toward donation or expanded leg-
islation to entice or require donation, it is unlikely that the 
current organ shortage will be rectified. Given an increase 
in the understanding of the mechanisms of antibody-
mediated rejection and the development of new agents for 
immunosuppression, cautious trials will help to identify 
the areas in which further research is warranted. The need 
to continue research into clinical xenotransplantation is 
highlighted in this environment. 
Informed consent is a matter of open discussions be-
tween the patient (and family) and his or her physician. 
Sufficient information must be supplied by the physician, 
without an air of assumption, in order for the patient to 
weigh the risks and benefits of the course that he or she is 
about to embark on. To the extent that regulatory com-
mittees view the informed consent process, they must en-
sure that the patient agrees by his or her own volition, 
without coercion, either overtly or subliminally, to partici-
pate, with the physicians not directly imparting their 
opinions or making the decision for the patient. It is diffi-
cult to determine the contribution of desperation to deci-
sion-making, especially when the alternative is death. In 
this light, regulatory forces may take on a surrogate role in 
preventing decisions based solely on "grasping at straws." 
In both of the baboon-to-human liver xenotransplant at-
tempts, the informed consent period encompassed 
lengthy discussions with the patients, their families. the 
transplant team. and third-party observers over a 7-day 
period. 
The scenario of unleashing a "doomsday" infectious 
agent on the human species has been forwarded by some. 77 
The possibility of transmission of infectious agents after 
xenotransplantation is finite, but it is the "unknown" 
agent that imparts caution in these trials.7s The risk of in-
fection when using either discordant or concordant 
donors should also be considered in the overall balance of 
risk-benefit discussions. On one hand, primate donors 
have the advantage of genetic similarity (and therefore, 
potential compatibility) and less risk of immunological 
loss. On the other hand. pig donors are more easily raised 
and are not sentient animals. Nevertheless, the possibilitv 
of disease transmission from porcine donors exists. 79 
Technological advances and better screening tools are 
likely to identify donors that may harbor latent infections 
or allow design of genetically engineered animals that may 
not be as susceptible to rejection. 
Xenotransplantation faces criticism that is strongly 
reminiscent of that leveled against human-ta-human 
transplantation in the late I 960s and early 1970s. Yet with 
persistence the field of human-to-human transplantation 
has proven to be highly successful. This success was the re-
sult of stepwise increases in understanding the biology of 
rejection. improvements in drug management. and expe-
rience. It is possible that xenotransplantation may not be 
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universally successful until further technological advances 
occur, yet cautious exploration of xenotransplantation 
appears warranted to identify those areas that will require 
further study.80 
CONCLUSIONS 
The trial and error of the cited pioneer trials 3 decades ago 
defined the human barrier to several species used. Success 
was tantalizingly close with the chimpanzee, baboon, and 
rhesus monkey (in that order). Although the chimpanzee 
has been shown to be a biologically superior donor (less ge-
netic diversity) in the early xenografting trials; the threat of 
extinction of chimpanzees precludes further such trials. In 
contrast, the baboon is easily raised in captivity and is not 
an endangered species. The difficulty of heterotransplan-
tation will vary with different organs. Because it is rela-
tively resistant to antibody-mediated rejection, the liver is 
the organ for which there is the greatest chance of success. 
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